
Jordan Isenstadt
SVP, Cannabis & PsychedelicsMarino PRJordan Isenstadt, SVP, Cannabis & Psychedelics, Marino PR
Jordan is a Senior Vice President at Marino, where he leads the Cannabis, Psychedelics & Emerging Industries practice. With a background in New York politics, public affairs, and nonprofit leadership, he brings a deep understanding of how regulation, media, and advocacy shape outcomes. At Marino, he advises operators and emerging brands on launching, scaling, licensing strategy, and market expansion. His work also includes engaging policymakers, attracting investors, and building credibility in highly regulated industries.
Jews in Weed Meetup
Community Meetups are hosted by organizations and companies with interest-specific content to help you find likeminded professionals.
Whether you’re t
…Community Meetups are hosted by organizations and companies with interest-specific content to help you find likeminded professionals.
Whether you’re trying to find your community, or enter a new sector, this is your chance to skip the digital outreac
…Community Meetups are hosted by organizations and companies with interest-specific content to help you find likeminded professionals.
Whether you’re trying to find your community, or enter a new sector, this is your chance to skip the digital outreach and meet new faces in-person.
Community Meetups are hosted by organizations and companies with interest-specific content to help you find likeminded professionals.
Whether you’re trying to find your community, or enter a new sector, this is your chance to skip the digital outreach and meet new faces in-person.
Show MoreClick the title to see all detailsThe Cannabinoid Drug Pipeline: From Clinical Trials to Market
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, s
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the indu
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next.
Cannabinoid-based pharmaceuticals are moving from promise to practice, with a growing pipeline of FDA-reviewed candidates targeting epilepsy, pain, sleep, and beyond. Yet the path from molecule to market remains one of the most demanding in the industry. This session gives pharmaceutical executives, investors, and researchers a perspective of where clinical development stands today and where the real cannabis industry opportunities sit next.
You'll learn how to navigate the FDA regulatory pathway, structure clinical trials that withstand scrutiny, and align early-stage research with cannabis business compliance expectations. We'll break down the drug development process stage by stage, then turn to commercialization: pricing, payer access, manufacturing scale, and partnership models that bring a cannabinoid drug to patients.
By the end, you'll leave with a strategic framework for evaluating pipelines, de-risking development, and timing market entry.

